Dissecting the molecular basis of high viscosity of monospecific and bispecific IgG antibodies

References

• The Antibody Society. List of approved antibodies. [cited 2019 Nov 19]. https://www.antibodysociety.org/resources/approved-antibodies/.
   Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17:197–11.
   PubMed Web of Science ®Google Scholar
• Viola M, Sequeira J, Seiça R, Veiga F, Serra J, Santos AC, Ribeiro AJ. Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release. 2018;286:301–14.
   PubMed Web of Science ®Google Scholar
• Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, Zhu XP, Zhou Q. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adher. 2015;9:923–42.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;11:239–64.
   PubMed Web of Science ®Google Scholar
• Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93:1390–402.
   PubMed Web of Science ®Google Scholar
• Hung JJ, Borwankar AU, Dear BJ, Truskett TM, Johnston KP. High concentration tangential flow ultrafiltration of stable monoclonal antibody solutions with low viscosities. J Membrane Sci. 2016;508:113–26.
   Web of Science ®Google Scholar
• Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci. 2005;94:1928–40.
   PubMed Web of Science ®Google Scholar
• Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci. 2010;99:1152–68.
   PubMed Web of Science ®Google Scholar
• Yadav S, Shire SJ, Kalonia DS. Viscosity behavior of high-concentration monoclonal antibody solutions: correlation with interaction parameter and electroviscous effects. J Pharm Sci-Us. 2012;101:998–1011.
   PubMed Web of Science ®Google Scholar
• Du W, Klibanov AM. Hydrophobic salts markedly diminish viscosity of concentrated protein solutions. Biotechnol Bioeng. 2011;108:632–36.
   PubMed Web of Science ®Google Scholar
• He F, Woods CE, Litowski JR, Roschen LA, Gadgil HS, Razinkov VI, Kerwin BA. Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm Res-Dordr. 2011;28:1552–60.
   PubMed Web of Science ®Google Scholar
• Esfandiary R, Hayes DB, Parupudi A, Casas-Finet J, Bai S, Samra HS, Shah AU, Sathish HA. A systematic multitechnique approach for detection and characterization of reversible self-association during formulation development of therapeutic antibodies. J Pharm Sci. 2013;102:62–72.
   PubMedGoogle Scholar
• Esfandiary R, Parupudi A, Casas-Finet J, Gadre D, Sathish H. Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions. J Pharm Sci. 2015;104:577–86.
   PubMed Web of Science ®Google Scholar
• Mason BD, Zhang L, Remmele RL Jr., Zhang J. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci. 2011;100:4587–96.
   PubMed Web of Science ®Google Scholar
• Melander W, Horvath C. Salt effect on hydrophobic interactions in precipitation and chromatography of proteins: an interpretation of the lyotropic series. Arch Biochem Biophys. 1977;183:200–15.
   PubMed Web of Science ®Google Scholar
• Nishi H, Miyajima M, Nakagami H, Noda M, Uchiyama S, Fukui K. Phase separation of an IgG1 antibody solution under a low ionic strength condition. Pharm Res. 2010;27:1348–60.
   PubMed Web of Science ®Google Scholar
• Pindrus M, Shire SJ, Kelley RF, Demeule B, Wong R, Xu Y, Yadav S. Solubility challenges in high concentration monoclonal antibody formulations: relationship with amino acid sequence and intermolecular interactions. Mol Pharm. 2015;12:3896–907.
   PubMed Web of Science ®Google Scholar
• Yadav S, Sreedhara A, Kanai S, Liu J, Lien S, Lowman H, Kalonia DS, Shire SJ. Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res-Dordr. 2011;28:1750–64.
   PubMed Web of Science ®Google Scholar
• Yadav S, Shire SJ, Kalonia DS. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci. 2010;99:4812–29.
   PubMed Web of Science ®Google Scholar
• Chari R, Jerath K, Badkar AV, Kalonia DS. Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions. Pharm Res-Dordr. 2009;26:2607–18.
   PubMed Web of Science ®Google Scholar
• Chow CK, Allan BW, Chai Q, Atwell S, Lu J. Therapeutic antibody engineering to improve viscosity and phase separation guided by crystal structure. Mol Pharm. 2016;13:915–23.
   PubMedGoogle Scholar
• Shan L, Mody N, Sormani P, Rosenthal KL, Damschroder MM, Esfandiary R. Developability assessment of engineered monoclonal antibody variants with a complex self-association behavior using complementary analytical and in silico tools. Mol Pharm. 2018;15:5697–710.
   PubMed Web of Science ®Google Scholar
• Geng SB, Wittekind M, Vigil A, Tessier PM. Measurements of monoclonal antibody self-association are correlated with complex biophysical properties. Mol Pharm. 2016;13:1636–45.
   PubMedGoogle Scholar
• Geoghegan JC, Fleming R, Damschroder M, Bishop SM, Sathish HA, Esfandiary R. Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering. MAbs. 2016;8:941–50.
   PubMed Web of Science ®Google Scholar
• Buck PM, Chaudhri A, Kumar S, Singh SK. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. Mol Pharm. 2015;12:127–39.
   PubMedGoogle Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106:11937–42.
   PubMed Web of Science ®Google Scholar
• Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. MAbs. 2015;7:212–30.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–106.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.
   PubMed Web of Science ®Google Scholar
• Woldeyes MA, Josephson LL, Leiske DL, Galush WJ, Roberts CJ, Furst EM. Viscosities and protein interactions of bispecific antibodies and their monospecific mixtures. Mol Pharm. 2018;15:4745–55.
   PubMed Web of Science ®Google Scholar
• Inoue N, Takai E, Arakawa T, Shiraki K. Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations. Mol Pharm. 2014;11:1889–96.
   PubMed Web of Science ®Google Scholar
• Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270:26–35.
   PubMed Web of Science ®Google Scholar
• Spiess C, Bevers J 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem. 2013;288:26583–93.
   PubMed Web of Science ®Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol. 2013;31:753–58.
   PubMed Web of Science ®Google Scholar
• Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos. 2010;38:84–91.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol. 2009;27:767–71.
   PubMed Web of Science ®Google Scholar
• Kanai S, Liu J, Patapoff TW, Shire SJ. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci. 2008;97:4219–27.
   PubMed Web of Science ®Google Scholar
• Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley RF, Wu LC, Eigenbrot C. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 2013;425:1330–39.
   PubMed Web of Science ®Google Scholar
• Peng K, Wang Y, Siradze K, Erickson R, Fischer SK, Staton TL. Measurement of IL-17AA and IL-17FF as pharmacodynamic biomarkers to demonstrate target engagement in the phase I study of MCAF5352A. Aaps J. 2019;21:9.
   Web of Science ®Google Scholar
• Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. Bethesda (MD): NIH; 1991.
   Google Scholar
• Traxlmayr MW, Kiefer JD, Srinivas RR, Lobner E, Tisdale AW, Mehta NK, Yang NJ, Tidor B, Wittrup KD. Strong enrichment of aromatic residues in binding sites from a charge-neutralized hyperthermostable Sso7d scaffold library. J Biol Chem. 2016;291:22496–508.
   PubMed Web of Science ®Google Scholar
• Koth CM, Murray JM, Mukund S, Madjidi A, Minn A, Clarke HJ, Wong T, Chiang V, Luis E, Estevez A, et al. Molecular basis for negative regulation of the glucagon receptor. Proc Natl Acad Sci U S A. 2012;109:14393–98.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE) 2013.08. Chemical Computing Group ULC, 1010 Sherbooke St. West, suite 910, Montreal, QC, Canada, H3A 2R7. 2018., 2018.
   Google Scholar
• Tomar DS, Kumar S, Singh SK, Goswami S, Li L. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. Mabs. 2016;8:216–28.
   PubMed Web of Science ®Google Scholar
• Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26:98–106.
   PubMed Web of Science ®Google Scholar
• Yelvington BJ. Subcutaneous Rituximab in follicular lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. J Adv Pract Oncol. 2018;9:530–34.
   PubMedGoogle Scholar
• Dent S, Ammendolea C, Christofides A, Edwards S, Incekol D, Pourmirza B, Kfoury S, Poirier B. A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Curr Oncol. 2019;26:e70–e80.
   PubMed Web of Science ®Google Scholar
• Kastelic M, Dill KA, Kalyuzhnyi YV, Vlachy V. Controlling the viscosities of antibody solutions through control of their binding sites. J Mol Liq. 2018;270:234–42.
   PubMed Web of Science ®Google Scholar
• Arora J, Hickey JM, Majumdar R, Esfandiary R, Bishop SM, Samra HS, Middaugh CR, Weis DD, Volkin DB. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody. MAbs. 2015;7:525–39.
   PubMed Web of Science ®Google Scholar
• Arora J, Hu Y, Esfandiary R, Sathish HA, Bishop SM, Joshi SB, Middaugh CR, Volkin DB, Weis DD. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity. MAbs. 2016;8:1561–74.
   PubMed Web of Science ®Google Scholar
• Sudrik C, Cloutier T, Pham P, Samra HS, Trout BL. Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies. MAbs. 2017;9:1155–68.
   PubMed Web of Science ®Google Scholar
• Dougherty DA. A computational study of cation-pi interactions vs salt bridges in aqueous media: implications for protein engineering. Peptides for the New Millennium. 2000;550–52.
   Google Scholar
• McGaughey GB, Gagné M, Rappé AK. pi-stacking interactions alive and well in proteins. J Biol Chem. 1998;273:15458–63.
   PubMed Web of Science ®Google Scholar
• Gallivan JP, Dougherty DA. A computational study of cation-pi interactions vs salt bridges in aqueous media: implications for protein engineering. J Am Chem Soc. 2000;122:870–74.
   Web of Science ®Google Scholar
• Mecozzi S, West AP Jr., Dougherty DA. Cation-pi interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide. Proc Natl Acad Sci U S A. 1996;93:10566–71.
   PubMed Web of Science ®Google Scholar
• Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol. 2018;38:394–408.
   PubMed Web of Science ®Google Scholar
• Li B, Fouts AE, Stengel K, Luan P, Dillon M, Liang WC, Feierbach B, Kelley RF, Hötzel I. In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. MAbs. 2014;6:437–45.
   PubMed Web of Science ®Google Scholar
• Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev. 2009;61:965–76.
   PubMed Web of Science ®Google Scholar
• Quarmby V, Phung QT, Lill JR. MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. Expert Rev Proteomics. 2018;15:733–48.
   PubMed Web of Science ®Google Scholar
• Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies Susceptibility vs. functionality of critical quality attributes. Mabs. 2014;6:327–39.
   PubMed Web of Science ®Google Scholar
• DiCara DM, Andersen N, Chan R, Ernst JA, Ayalon G, Lazar GA, Agard NJ, Hilderbrand A, Hotzel I. High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants. Mabs. 2018;10:1073–83.
   PubMed Web of Science ®Google Scholar
• Yang XY, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development Improving manufacturability of monoclonal antibodies. Mabs. 2013;5:787–94.
   PubMed Web of Science ®Google Scholar
• Josephson LL, Galush WJ, Furst EM. Parallel temperature-dependent microrheological measurements in a microfluidic chip. Biomicrofluidics. 2016;10:043503.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Watanabe A, Hayasaka A, Muraoka M, Hori Y, Yamazaki T, Imaeda Y, Koga A. Small-scale screening method for low-viscosity antibody solutions using small-angle X-ray scattering. Eur J Pharm Biopharm. 2017;112:132–37.
   PubMed Web of Science ®Google Scholar
• Tomar DS, Singh SK, Li L, Broulidakis MP, Kumar S. In Silico Prediction of Diffusion Interaction Parameter (kD), a Key Indicator of Antibody Solution Behaviors. Pharm Res. 2018;35:193.
   PubMed Web of Science ®Google Scholar
• Zhu K, Day T, Warshaviak D, Murrett C, Friesner R, Pearlman D. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins. 2014;82:1646–55.
   PubMed Web of Science ®Google Scholar
• Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods. 2002;263:133–47.
   PubMed Web of Science ®Google Scholar
• Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochem. 1986;25:8343–47.
   PubMed Web of Science ®Google Scholar
• Polson AG, Yu SF, Elkins K, Zheng B, Clark S, Ingle GS, Slaga DS, Giere L, Du C, Tan C, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007;110:616–23.
   PubMed Web of Science ®Google Scholar
• Beard H, Cholleti A, Pearlman D, Sherman W, Loving KA. Applying physics-based scoring to calculate free energies of binding for single amino acid mutations in protein-protein complexes. PLoS One. 2013;8:e82849.
   Web of Science ®Google Scholar
• Bos AB, Luan P, Duque JN, Reilly D, Harms PD, Wong AW. Optimization and automation of an end-to-end high throughput microscale transient protein production process. Biotechnol Bioeng. 2015;112:1832–42.
   PubMed Web of Science ®Google Scholar